NCT05631626 - Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 29, 2022

Primary Completion Date

June 13, 2023

Study Completion Date

June 13, 2023

Conditions

ADHDADHD - Combined TypeAttention Deficit Hyperactivity Disorder CombinedAttention Deficit Hyperactivity Disorder

Interventions

DRUG

CTx-1301 - Dexmethylphenidate 25mg

25mg CTx-1301 (Dexmethylphenidate tablet)

DRUG

CTx-1301 - Dexmethylphenidate 37.5mg

37.5mg CTx-1301 (Dexmethylphenidate tablet)

DRUG

CTx-1301 - Dexmethylphenidate 50mg

50mg CTx-1301 (Dexmethylphenidate tablet)

DRUG

Placebo

Trial Locations (1)

Clinical Research of Southern Nevada, LLC, Las Vegas